Annual report pursuant to Section 13 and 15(d)

Condensed Consolidating Financial Information (Details 1)

v3.4.0.3
Condensed Consolidating Financial Information (Details 1) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Feb. 29, 2016
Nov. 30, 2015
Aug. 31, 2015
May. 31, 2015
Feb. 28, 2015
Nov. 30, 2014
Aug. 31, 2014
May. 31, 2014
Feb. 29, 2016
Feb. 28, 2015
Feb. 28, 2014
Condensed Consolidating Statement of Comprehensive Income                      
Sales                 $ 7,223.8 $ 6,672.1 $ 5,411.0
Less – excise taxes                 (675.4) (644.1) (543.3)
Net sales $ 1,543.2 $ 1,640.5 $ 1,733.4 $ 1,631.3 $ 1,356.2 $ 1,541.7 $ 1,604.1 $ 1,526.0 6,548.4 6,028.0 4,867.7
Cost of product sold                 (3,606.1) (3,449.4) (2,876.0)
Gross profit 696.1 733.5 775.6 737.1 597.6 638.9 672.0 670.1 2,942.3 2,578.6 1,991.7
Selling, general and administrative expenses                 (1,177.2) (1,078.4) (895.1)
Operating income                 1,765.1 1,500.2 2,437.7
Equity in earnings of equity method investees and subsidiaries                 26.6 21.5 87.8
Dividend income                 24.5    
Interest income                 0.8 1.4 7.7
Intercompany interest income                 0.0 0.0 0.0
Interest expense                 (314.7) (339.1) (330.9)
Intercompany interest expense                 0.0 0.0 0.0
Loss on write-off of debt issuance costs                 (1.1) (4.4) 0.0
Income before income taxes                 1,501.2 1,179.6 2,202.3
(Provision for) benefit from income taxes                 (440.6) (343.4) (259.2)
Net income                 1,060.6 836.2 1,943.1
Net (income) loss attributable to noncontrolling interests                 (5.7) 3.1 0.0
Net income attributable to CBI $ 243.4 $ 270.5 $ 302.4 $ 238.6 $ 214.6 $ 222.2 $ 195.8 $ 206.7 1,054.9 839.3 1,943.1
Comprehensive income attributable to CBI                 733.3 622.4 1,897.0
Impairment of goodwill and intangible assets                 0.0 0.0 (300.9)
Gain on remeasurement to fair value of equity method investment                 0.0 0.0 1,642.0
Parent Company [Member]                      
Condensed Consolidating Statement of Comprehensive Income                      
Sales                 2,522.8 2,406.4 2,351.8
Less – excise taxes                 (332.6) (324.8) (317.3)
Net sales                 2,190.2 2,081.6 2,034.5
Cost of product sold                 (1,759.6) (1,678.4) (1,730.3)
Gross profit                 430.6 403.2 304.2
Selling, general and administrative expenses                 (378.4) (388.2) (395.4)
Operating income                 52.2 15.0 (91.2)
Equity in earnings of equity method investees and subsidiaries                 1,224.2 828.0 2,219.2
Dividend income                 0.0    
Interest income                 0.2 0.1 0.1
Intercompany interest income                 191.4 177.8 152.4
Interest expense                 (290.1) (296.4) (283.2)
Intercompany interest expense                 (267.4) (222.0) (168.1)
Loss on write-off of debt issuance costs                 (0.4) 0.0  
Income before income taxes                 910.1 502.5 1,829.2
(Provision for) benefit from income taxes                 144.8 336.8 113.9
Net income                 1,054.9 839.3 1,943.1
Net (income) loss attributable to noncontrolling interests                 0.0 0.0 0.0
Net income attributable to CBI                 1,054.9 839.3 1,943.1
Comprehensive income attributable to CBI                 733.3 622.4 1,897.0
Impairment of goodwill and intangible assets                     0.0
Gain on remeasurement to fair value of equity method investment                     0.0
Subsidiary Guarantors [Member]                      
Condensed Consolidating Statement of Comprehensive Income                      
Sales                 5,614.9 5,078.3 3,868.3
Less – excise taxes                 (281.1) (251.6) (155.9)
Net sales                 5,333.8 4,826.7 3,712.4
Cost of product sold                 (3,906.2) (3,629.0) (2,661.6)
Gross profit                 1,427.6 1,197.7 1,050.8
Selling, general and administrative expenses                 (652.6) (470.1) (361.7)
Operating income                 775.0 727.6 2,331.1
Equity in earnings of equity method investees and subsidiaries                 31.2 24.6 92.7
Dividend income                 0.0    
Interest income                 0.0 0.0 0.0
Intercompany interest income                 268.0 222.7 168.5
Interest expense                 (0.2) (1.4) (2.5)
Intercompany interest expense                 (191.3) (177.6) (153.6)
Loss on write-off of debt issuance costs                 0.0 0.0  
Income before income taxes                 882.7 795.9 2,436.2
(Provision for) benefit from income taxes                 (346.3) (295.5) (292.5)
Net income                 536.4 500.4 2,143.7
Net (income) loss attributable to noncontrolling interests                 0.0 0.0 0.0
Net income attributable to CBI                 536.4 500.4 2,143.7
Comprehensive income attributable to CBI                 531.9 503.7 2,167.7
Impairment of goodwill and intangible assets                     0.0
Gain on remeasurement to fair value of equity method investment                     1,642.0
Subsidiary Nonguarantors [Member]                      
Condensed Consolidating Statement of Comprehensive Income                      
Sales                 3,024.5 3,004.1 2,093.9
Less – excise taxes                 (61.7) (67.7) (70.1)
Net sales                 2,962.8 2,936.4 2,023.8
Cost of product sold                 (1,823.8) (1,870.3) (1,312.1)
Gross profit                 1,139.0 1,066.1 711.7
Selling, general and administrative expenses                 (176.5) (273.4) (155.0)
Operating income                 962.5 792.7 255.8
Equity in earnings of equity method investees and subsidiaries                 0.5 1.2 0.6
Dividend income                 24.5    
Interest income                 0.6 1.3 7.6
Intercompany interest income                 0.1 0.0 1.5
Interest expense                 (24.4) (41.3) (45.2)
Intercompany interest expense                 (0.8) (0.9) (0.7)
Loss on write-off of debt issuance costs                 (0.7) (4.4)  
Income before income taxes                 962.3 748.6 219.6
(Provision for) benefit from income taxes                 (247.4) (395.7) (100.1)
Net income                 714.9 352.9 119.5
Net (income) loss attributable to noncontrolling interests                 (5.7) 3.1 0.0
Net income attributable to CBI                 709.2 356.0 119.5
Comprehensive income attributable to CBI                 383.7 132.2 64.0
Impairment of goodwill and intangible assets                     (300.9)
Gain on remeasurement to fair value of equity method investment                     0.0
Eliminations [Member]                      
Condensed Consolidating Statement of Comprehensive Income                      
Sales                 (3,938.4) (3,816.7) (2,903.0)
Less – excise taxes                 0.0 0.0 0.0
Net sales                 (3,938.4) (3,816.7) (2,903.0)
Cost of product sold                 3,883.5 3,728.3 2,828.0
Gross profit                 (54.9) (88.4) (75.0)
Selling, general and administrative expenses                 30.3 53.3 17.0
Operating income                 (24.6) (35.1) (58.0)
Equity in earnings of equity method investees and subsidiaries                 (1,229.3) (832.3) (2,224.7)
Dividend income                 0.0    
Interest income                 0.0 0.0 0.0
Intercompany interest income                 (459.5) (400.5) (322.4)
Interest expense                 0.0 0.0 0.0
Intercompany interest expense                 459.5 400.5 322.4
Loss on write-off of debt issuance costs                 0.0 0.0  
Income before income taxes                 (1,253.9) (867.4) (2,282.7)
(Provision for) benefit from income taxes                 8.3 11.0 19.5
Net income                 (1,245.6) (856.4) (2,263.2)
Net (income) loss attributable to noncontrolling interests                 0.0 0.0 0.0
Net income attributable to CBI                 (1,245.6) (856.4) (2,263.2)
Comprehensive income attributable to CBI                 $ (915.6) $ (635.9) (2,231.7)
Impairment of goodwill and intangible assets                     0.0
Gain on remeasurement to fair value of equity method investment                     $ 0.0